Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Cancer Res. 2015 Nov 20;76(3):664–674. doi: 10.1158/0008-5472.CAN-15-0828

Figure 1. Model of FL transformation to DLBCL and experimental approach to abrogate transformed gene signature.

Figure 1

GCB derived aberrant FL cells after acquiring new oncogenic events undergo further transformation to DLBCL. These new aberrations cause erroneous downstream signaling of genes called MRs. Targeting of activated MR by siRNA/shRNA silencing or small molecule inhibition should impair their regulatory function and abrogate the FL transformed signature.